Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Opioid Use Disorder: early-phase trial registry
156 of 258 indexed Opioid Use Disorder trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #40 of 28,707 conditions by registered trial count.
258 US clinical trials · 156 currently recruiting · #40 of 28,707 conditions by registered trial count
Opioid Use Disorder: 258 US clinical trials tracked, 156 recruiting.
Opioid Use Disorder is the subject of 258 registered US clinical trials on ClinicalTrials.gov, 156 of them currently open to new participants. 23 are in Phase 3-4 (later-stage) and 59 in Phase 1-2 (earlier-stage). The most active sponsor is Yale University, running 19 of these trials.
Enrollment posture brief
Registry condition opioid-use-disorder
OPEN 156 | RECR 60% | LATE 23 | EARLY 59 | RANK #40 | SPON 19
Volume-matched condition peers
Nearest open-share peer: HIV Prevention (61% recruiting · 33 trials)
Opioid Use Disorder lists 156 open slots (60% of 258 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Opioid Use Disorder on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Opioid Use Disorder is recruiting above its size-band peers.
156 of 258 indexed trials (60.5%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Opioid Use Disorder trials is spread across many organizations.
Yale University accounts for 19 of 258 trials (7.4%). 127 distinct sponsors appear on at least one study for this condition label.
-
Typical Opioid Use Disorder enrolment sits around 103 participants.
Median target enrolment is 103 among the 258 trials that report a genuine target (sentinel values excluded). 121 of those (46.9%) plan for fewer than 100 participants.
-
Opioid Use Disorder research is mostly interventional.
233 interventional and 25 observational studies make up this index (90.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
258 total, page 3 of 6
Using Facebook to Support Opioid Recovery Among American Indian Women
Mayo Clinic
NCT05995886
A Clinical Trial Comparing Buprenorphine Formulations for High Potency Synthetic Opioid Use
Rachel R. Luba
NCT06726200
Trauma Screening/Referral and Interpersonal Violence Prevention for Women with Substance Use Disorders
Clemson University
NCT06608979
Evaluation of the Interactions of Cannabidiol (CBD) With Morphine
National Institute on Drug Abuse (NIDA)
NCT05143424
Better Experiences in Substance Treatment: A Brief Alcohol-focused Intervention Tailored for Patients in Opioid Agonist Treatment
University of Notre Dame
NCT07342504
A Study to Test Whether BI 1356225 Improves Impulsive Behavior in People With Opioid Use Disorder Who Are Taking Buprenorphine
Boehringer Ingelheim
NCT06628622
Rapid Outpatient Low-dose Initiation of Buprenorphine for OUD With Fentanyl Use
University of Pennsylvania
NCT06379984
Assessing a Clinically-meaningful Opioid Withdrawal Phenotype
University of Maryland, Baltimore
NCT05027919
Multi-System Analysis of Opioid Receptor Binding
University of Pennsylvania
NCT05528848
Ketamine Assisted Psychotherapy for Opioid Use Disorder
University of Utah
NCT04892251
Opioid Use and Criminal Justice: Intervening to Improve the Outcomes of Women
Abenaa Jones, Ph.D.
NCT06682364
Ketamine for Opioid Use Disorder
University of Maryland, Baltimore
NCT06943859
Postpartum Intervention for Mothers With Opioid Use Disorders
Stony Brook University
NCT05614661
An Intervention Mapping Approach to Closing the Gap in Maternal OUD and Infant NAS Care (SUPPORT)
University of Pennsylvania
NCT06576323
Mobile Platform for Optimizing Wellness and Engagement in Recovery
University of Michigan
NCT07178990
Semaglutide for Helping Opioid Recovery
Brigham and Women's Hospital
NCT06639464
Clinical Trials of Multivalent Opioid Vaccine Components
New York State Psychiatric Institute
NCT04458545
Development of an mHealth Behavioral Sleep Medicine Intervention for Use During Medication Assisted Treatment for MOUD
Medical University of South Carolina
NCT06157840
Study to Assess the Use of Tezampanel for Opioid Withdrawal Syndrome in Treatment-Seeking Patients With Opioid Use Disorder
Proniras Corporation
NCT06538558
MBC2OTP Project (Measurement-Based Care Implementation in Community Opioid Treatment Programs)
Northwestern University
NCT06345274
Brain Training for Substance Use Disorders
Neurotype
NCT06870110
Retention and Re-Engagement in Treatment for Addiction Following Serious Injection Related Infections (RETAIN)
Boston Medical Center
NCT06489535
Transdermal Patch for BupRenorphine Induction DurinG PrEgnancy (Patch BRIDGE)
Washington University School of Medicine
NCT05790252
Technology-Enhanced Therapy vs. Medication Monitoring for Buprenorphine Retention in Pregnant Persons
Medical University of South Carolina
NCT06999811
Wellcome Leap Psilocybin for OUD
Anna Rose Childress, Ph.D.
NCT06786325
EXPANDED SCOPE for Parent Grant Entitled, "Peer Recovery Support Services for Individuals in Recovery Residences on MOUD"
Potomac Health Foundations
NCT06696157
Cannabidiol in Opioid Use Disorder and Chronic Pain
Yale University
NCT04587791
LIFU for Treatment for Refractory Opioid Use Disorder
Ali Rezai
NCT06218706
Autobiographical Memory in Opioid Use Disorder
University of Pennsylvania
NCT06643988
OMAR Opioid Use Disorder
Yale University
NCT05683184
Emotional Awareness and Expression Therapy for Chronic Pain and Opioid Use Disorder
University of Michigan
NCT06865560
HIV, Equity, and Addiction Training (HEAT) Program
University of Alabama at Birmingham
NCT06370481
Extended-release Buprenorphine as a Novel Low-dose Induction Strategy
Brigham and Women's Hospital
NCT06441604
Neuromodulation and Cognitive Training in Opioid Use Disorder
University of Minnesota
NCT03773523
Exablate for LIFU Neuromodulation in Patients With Opioid Use Disorder (OUD) and/or Other Substance Use Disorders (SUDs)
InSightec
NCT04197921
Focused Ultrasound for the Complex Patient
Washington D.C. Veterans Affairs Medical Center
NCT06453109
Low-Intensity Focused Ultrasound and the Complex Patient
Virginia Polytechnic Institute and State University
NCT06297200
Injectable Extended-Release Buprenorphine (XR-B) in a Correctional Setting: Qualitative Interviews
Lifespan
NCT06354465
Behavioral Pharmacological Examination of a Novel Buprenorphine Induction Method Among Individuals Who Use Fentanyl
Johns Hopkins University
NCT06089707
Psilocybin on Brain Mechanisms of Motivation in OUD
Anna Rose Childress, Ph.D.
NCT06810310
Behavioral Effects of Drugs (Inpatient): 43 (Opioids, Cocaine, n-Acetylcysteine)
William Stoops
NCT05610072
STTEPP: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis
Indiana University
NCT05603702
Adjunctive Bright Light Therapy for Opioid Use Disorder
Arizona State University
NCT05459922
Pilot Testing a Novel Remotely Delivered Intensive Outpatient Program for Individuals With OUD
Brigham and Women's Hospital
NCT05817825
Adapting the Penny Chatbot for Perinatal OUD Patients: COPILOT
University of Pennsylvania
NCT06969261
Evaluation of a Patient Decision Aid for Emergency Department Initiated Buprenorphine
Medical University of South Carolina
NCT07278518
Sensing Physiological Symptoms of Opioid Withdrawal and Cravings in Patients With Opioid Use Disorder
Spark Biomedical
NCT06487533
Cannabis and Opioid Use Disorder
University of Kentucky
NCT05729932
MDMA for Co-occurring PTSD and OUD After Childbirth
University of New Mexi
NCT05219175
Open Pilot Trial of Adapted Cognitive Processing Therapy for Comorbid PTSD and Opioid Use Disorder
The City College of New York
NCT06872164
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 27 |
| Phase 2 | 32 |
| Phase 3 | 12 |
| Phase 4 | 11 |
Top Sponsors
Named interventions
Most-linked intervention names on Opioid Use Disorder records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Opioid Use Disorder trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Opioid Use Disorder page
258 registered trials, 156 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 156 Opioid Use Disorder trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Yale University sponsors the most Opioid Use Disorder trials on record, review their full trial history before evaluating a specific study. See Yale University's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Opioid Use Disorder condition card totals 258 registered trials; most-linked intervention Placebo; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.